{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T22:55:40Z","timestamp":1781650540392,"version":"3.54.5"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:00Z","timestamp":1776384000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T00:00:00Z","timestamp":1776643200000},"content-version":"vor","delay-in-days":3,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82300949"],"award-info":[{"award-number":["82300949"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82170880"],"award-info":[{"award-number":["82170880"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"the 333 High Level Talents Training Project of Jiangsu Province"},{"name":"the Nanjing Medical Science and Technique Development Foundation","award":["ZKX23041"],"award-info":[{"award-number":["ZKX23041"]}]},{"name":"the Science and Technology Department of Jiangsu Province","award":["BE2023745"],"award-info":[{"award-number":["BE2023745"]}]},{"name":"the Health Commission of Jiangsu Province","award":["H2023137"],"award-info":[{"award-number":["H2023137"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Biol Direct"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Diabetic nephropathy (DN) is a leading cause of end-stage renal disease worldwide. Sodium-glucose cotransporter-2 inhibitors (SGLT2is), such as dapagliflozin, have demonstrated renoprotective effects in the treatment of DN. In addition to kidney protection, SGLT2is confer significant cardiovascular and hepatic benefits; however, the mechanisms underlying these multi-organ protective effects have not yet been fully elucidated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A total of 51 patients with newly diagnosed DN were enrolled and received dapagliflozin treatment (10\u00a0mg\/day; AstraZeneca) for 12 weeks. Circulating lipid profiles were analyzed using untargeted lipidomics. To further characterize renal lipid alterations, spatial metabolomics was performed on kidney tissues obtained from dapagliflozin-treated\n                      <jats:italic>db\/db<\/jats:italic>\n                      mice.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Dapagliflozin treatment significantly reduced serum triglyceride levels while increasing high-density lipoprotein cholesterol in DN patients. Untargeted lipidomic analysis revealed extensive remodeling of the circulating lipidome, marked by reductions in pro-fibrotic and pro-inflammatory lipid species and concurrent increases in renoprotective lipids, including fatty acid esters of hydroxy fatty acids. Machine-learning analyses identified specific lipid ratio changes that were positively correlated with renal function parameters, notably ratios involving SM(d14:0\/30:1) and PC(16:0e\/18:2). Furthermore, spatial metabolomic profiling in db\/db mice demonstrated that dapagliflozin alleviated renal lipotoxicity by reducing the accumulation of toxic lipid species and promoting lipid redistribution predominantly within the renal cortex. Mechanistically, dapagliflozin treatment was associated with enhanced renal fatty acid \u03b2-oxidation and sphingolipid degradation while suppressing key anabolic pathways, including de novo lipogenesis and glycerophospholipid and sphingolipid biosynthesis. These metabolic alterations were further evidenced by altered expression of key regulatory enzymes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Dapagliflozin is associated with remodeling of renal lipid metabolism in DN, accompanied by improvements in systemic lipid profile. The improvement in circulating dyslipidemia may partially explain the cardiovascular and hepatic protective effects associated with dapagliflozin therapy. Collectively, these findings provide mechanistic insight into the lipid-mediated, multi-organ benefits of dapagliflozin in DN.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13062-026-00800-9","type":"journal-article","created":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T10:54:49Z","timestamp":1776423289000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Dapagliflozin induces renal lipidomic remodeling and systemic metabolic improvement"],"prefix":"10.1186","volume":"21","author":[{"given":"Anni","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxuan","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinlin","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiawei","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangyang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenbo","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,17]]},"reference":[{"key":"800_CR1","doi-asserted-by":"crossref","unstructured":"Qiao X, et al. Longitudinal trajectories of albuminuria and eGFR in Type 2 Diabetes Mellitus: natural progression of diabetic kidney disease. J Diabetes Res. 2025;2025:p. 9269085.","DOI":"10.1155\/jdr\/9269085"},{"issue":"4","key":"800_CR2","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/S0272-6386(86)80031-2","volume":"8","author":"DF Kappel","year":"1986","unstructured":"Kappel DF, Van Tuinen M. Trends in the incidence of treated end-stage renal disease secondary to diabetic nephropathy: 1975\u20131984. Am J Kidney Dis. 1986;8(4):234\u20138.","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"800_CR3","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1111\/dom.70378","volume":"28","author":"S Zhang","year":"2026","unstructured":"Zhang S, et al. Global prevalence of chronic kidney disease in type 1 diabetes: A systematic review and meta-analysis. Diabetes Obes Metab. 2026;28(3):1924\u201333.","journal-title":"Diabetes Obes Metab"},{"issue":"6S1","key":"800_CR4","doi-asserted-by":"publisher","first-page":"A8","DOI":"10.1053\/j.ajkd.2025.02.602","volume":"85","author":"KL Johansen","year":"2025","unstructured":"Johansen KL, et al. US Renal Data System 2024 Annual Data Report: Epidemiology of Kidney Disease in the United States. Am J Kidney Dis. 2025;85(6S1):A8\u201311.","journal-title":"Am J Kidney Dis"},{"issue":"12","key":"800_CR5","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.2215\/CJN.11491116","volume":"12","author":"RZ Alicic","year":"2017","unstructured":"Alicic RZ, Rooney MT, Tuttle KR. Diabetic Kidney Disease: Challenges, Progress, and Possibilities. Clin J Am Soc Nephrol. 2017;12(12):2032\u201345.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"5","key":"800_CR6","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1097\/CM9.0000000000003428","volume":"138","author":"J Li","year":"2025","unstructured":"Li J, et al. Epidemiological status, development trends, and risk factors of disability-adjusted life years due to diabetic kidney disease: A systematic analysis of Global Burden of Disease Study 2021. Chin Med J (Engl). 2025;138(5):568\u201378.","journal-title":"Chin Med J (Engl)"},{"key":"800_CR7","doi-asserted-by":"publisher","first-page":"109119","DOI":"10.1016\/j.diabres.2021.109119","volume":"183","author":"H Sun","year":"2022","unstructured":"Sun H, et al. Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2022;183:109119.","journal-title":"Diabetes Res Clin Pract"},{"issue":"12","key":"800_CR8","doi-asserted-by":"publisher","first-page":"5950","DOI":"10.1111\/dom.15969","volume":"26","author":"S Shan","year":"2024","unstructured":"Shan S, et al. Cross-country inequalities in disease burden and care quality of chronic kidney disease due to type 2 diabetes mellitus, 1990\u20132021: Findings from the global burden of disease study 2021. Diabetes Obes Metab. 2024;26(12):5950\u20139.","journal-title":"Diabetes Obes Metab"},{"key":"800_CR9","doi-asserted-by":"crossref","unstructured":"Lin R, et al. Comparison of the renal outcomes of novel antidiabetic agents in patients with type 2 diabetes with chronic kidney disease: a systematic review and network meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2025.","DOI":"10.1111\/dom.70224"},{"issue":"1","key":"800_CR10","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.pcd.2024.12.002","volume":"19","author":"D Orozco-Beltran","year":"2025","unstructured":"Orozco-Beltran D, et al. Glycemic and weight control in people with type 2 diabetes: A real-world observational study in primary care. Prim Care Diabetes. 2025;19(1):7\u201314.","journal-title":"Prim Care Diabetes"},{"key":"800_CR11","doi-asserted-by":"publisher","first-page":"e083039","DOI":"10.1136\/bmj-2024-083039","volume":"390","author":"K Nong","year":"2025","unstructured":"Nong K, et al. Medications for adults with type 2 diabetes: a living systematic review and network meta-analysis. BMJ. 2025;390:e083039.","journal-title":"BMJ"},{"issue":"10","key":"800_CR12","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1007\/s00125-018-4656-5","volume":"61","author":"C Ghezzi","year":"2018","unstructured":"Ghezzi C, Loo DDF, Wright EM. Physiology of renal glucose handling via SGLT1, SGLT2 and GLUT2. Diabetologia. 2018;61(10):2087\u201397.","journal-title":"Diabetologia"},{"key":"800_CR13","doi-asserted-by":"publisher","first-page":"218","DOI":"10.3389\/fphar.2014.00218","volume":"5","author":"O Demin Jr","year":"2014","unstructured":"Demin O Jr., et al. Analysis of the efficacy of SGLT2 inhibitors using semi-mechanistic model. Front Pharmacol. 2014;5:218.","journal-title":"Front Pharmacol"},{"issue":"2","key":"800_CR14","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s00125-016-4157-3","volume":"60","author":"V Vallon","year":"2017","unstructured":"Vallon V, Thomson SC. Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition. Diabetologia. 2017;60(2):215\u201325.","journal-title":"Diabetologia"},{"issue":"10","key":"800_CR15","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.1007\/s00125-018-4654-7","volume":"61","author":"T Rieg","year":"2018","unstructured":"Rieg T, Vallon V. Development of SGLT1 and SGLT2 inhibitors. Diabetologia. 2018;61(10):2079\u201386.","journal-title":"Diabetologia"},{"issue":"6","key":"800_CR16","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1161\/CIRCULATIONAHA.123.067584","volume":"149","author":"BL Neuen","year":"2024","unstructured":"Neuen BL, et al. Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and Albuminuria. Circulation. 2024;149(6):450\u201362.","journal-title":"Circulation"},{"key":"800_CR17","doi-asserted-by":"publisher","first-page":"104215","DOI":"10.1016\/j.ebiom.2022.104215","volume":"83","author":"YM Gao","year":"2022","unstructured":"Gao YM, et al. Cardiorenal protection of SGLT2 inhibitors-Perspectives from metabolic reprogramming. EBioMedicine. 2022;83:104215.","journal-title":"EBioMedicine"},{"issue":"18","key":"800_CR18","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1161\/CIRCULATIONAHA.122.061732","volume":"146","author":"M Packer","year":"2022","unstructured":"Packer M. Critical Reanalysis of the Mechanisms Underlying the Cardiorenal Benefits of SGLT2 Inhibitors and Reaffirmation of the Nutrient Deprivation Signaling\/Autophagy Hypothesis. Circulation. 2022;146(18):1383\u2013405.","journal-title":"Circulation"},{"key":"800_CR19","doi-asserted-by":"publisher","first-page":"154918","DOI":"10.1016\/j.metabol.2021.154918","volume":"126","author":"H Liu","year":"2022","unstructured":"Liu H, et al. Cardiorenal protection with SGLT2 inhibitors in patients with diabetes mellitus: from biomarkers to clinical outcomes in heart failure and diabetic kidney disease. Metabolism. 2022;126:154918.","journal-title":"Metabolism"},{"issue":"11","key":"800_CR20","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/S2213-8587(21)00242-4","volume":"9","author":"HJL Heerspink","year":"2021","unstructured":"Heerspink HJL, et al. Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial. Lancet Diabetes Endocrinol. 2021;9(11):743\u201354.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"800_CR21","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott SD, et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2019;380(4):347\u201357.","journal-title":"N Engl J Med"},{"key":"800_CR22","doi-asserted-by":"publisher","first-page":"e081820","DOI":"10.1136\/bmj-2024-081820","volume":"388","author":"Y Liu","year":"2025","unstructured":"Liu Y, et al. Dapagliflozin plus calorie restriction for remission of type 2 diabetes: multicentre, double blind, randomised, placebo controlled trial. BMJ. 2025;388:e081820.","journal-title":"BMJ"},{"issue":"2","key":"800_CR23","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1001\/jamacardio.2020.4511","volume":"6","author":"DK McGuire","year":"2021","unstructured":"McGuire DK, et al. Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: A Meta-analysis. JAMA Cardiol. 2021;6(2):148\u201358.","journal-title":"JAMA Cardiol"},{"key":"800_CR24","doi-asserted-by":"publisher","first-page":"e083735","DOI":"10.1136\/bmj-2024-083735","volume":"389","author":"J Lin","year":"2025","unstructured":"Lin J, et al. Effect of dapagliflozin on metabolic dysfunction-associated steatohepatitis: multicentre, double blind, randomised, placebo controlled trial. BMJ. 2025;389:e083735.","journal-title":"BMJ"},{"issue":"5","key":"800_CR25","doi-asserted-by":"publisher","first-page":"931","DOI":"10.2337\/dc18-1569","volume":"42","author":"A Latva-Rasku","year":"2019","unstructured":"Latva-Rasku A, et al. The SGLT2 Inhibitor Dapagliflozin Reduces Liver Fat but Does Not Affect Tissue Insulin Sensitivity: A Randomized, Double-Blind, Placebo-Controlled Study With 8-Week Treatment in Type 2 Diabetes Patients. Diabetes Care. 2019;42(5):931\u20137.","journal-title":"Diabetes Care"},{"issue":"1","key":"800_CR26","doi-asserted-by":"publisher","first-page":"10832","DOI":"10.1038\/s41598-024-61590-6","volume":"14","author":"G Cuatrecasas","year":"2024","unstructured":"Cuatrecasas G, et al. Dapagliflozin added to metformin reduces perirenal fat layer in type 2 diabetic patients with obesity. Sci Rep. 2024;14(1):10832.","journal-title":"Sci Rep"},{"issue":"1","key":"800_CR27","doi-asserted-by":"publisher","first-page":"3236","DOI":"10.1038\/s41598-022-07250-z","volume":"12","author":"C L\u00f3pez-Cano","year":"2022","unstructured":"L\u00f3pez-Cano C, et al. Dapagliflozin plus exenatide on patients with type 2 diabetes awaiting bariatric surgery in the DEXBASU study. Sci Rep. 2022;12(1):3236.","journal-title":"Sci Rep"},{"issue":"5","key":"800_CR28","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.55730\/1300-0144.5683","volume":"53","author":"P Akhanli","year":"2023","unstructured":"Akhanli P, et al. Impact of 24-week dapagliflozin treatment on body weight, body composition, and cardiac risk indicators of patients with type-2 diabetes mellitus. Turk J Med Sci. 2023;53(5):1178\u201384.","journal-title":"Turk J Med Sci"},{"key":"800_CR29","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.freeradbiomed.2025.04.028","volume":"234","author":"H Hu","year":"2025","unstructured":"Hu H, et al. Dapagliflozin attenuates diabetes-induced podocyte lipotoxicity via ERR\u03b1-Mediated lipid metabolism. Free Radic Biol Med. 2025;234:178\u201391.","journal-title":"Free Radic Biol Med"},{"issue":"1","key":"800_CR30","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s13098-024-01271-6","volume":"16","author":"J Sun","year":"2024","unstructured":"Sun J, et al. Dapagliflozin improves podocytes injury in diabetic nephropathy via regulating cholesterol balance through KLF5 targeting the ABCA1 signalling pathway. Diabetol Metab Syndr. 2024;16(1):38.","journal-title":"Diabetol Metab Syndr"},{"key":"800_CR31","doi-asserted-by":"crossref","unstructured":"Wang D, et al. The Sodium-Glucose Cotransporter 2 inhibitor dapagliflozin prevents renal and liver disease in western diet induced obesity mice. Int J Mol Sci. 2018;19(1).","DOI":"10.3390\/ijms19010137"},{"key":"800_CR32","doi-asserted-by":"publisher","first-page":"106531","DOI":"10.1016\/j.ejps.2023.106531","volume":"189","author":"J Wei","year":"2023","unstructured":"Wei J, et al. RNA-Seq transcriptome analysis of renal tissue from spontaneously hypertensive rats revealed renal protective effects of dapagliflozin, an inhibitor of sodium-glucose cotransporter 2. Eur J Pharm Sci. 2023;189:106531.","journal-title":"Eur J Pharm Sci"},{"issue":"6","key":"800_CR33","doi-asserted-by":"publisher","first-page":"3960","DOI":"10.1002\/ehf2.14987","volume":"11","author":"J Li","year":"2024","unstructured":"Li J, et al. SGLT2 inhibition, blood lipids, and cardiovascular disease: A Mendelian randomization study. ESC Heart Fail. 2024;11(6):3960\u201371.","journal-title":"ESC Heart Fail"},{"key":"800_CR34","doi-asserted-by":"publisher","first-page":"105068","DOI":"10.1016\/j.phrs.2020.105068","volume":"160","author":"A S\u00e1nchez-Garc\u00eda","year":"2020","unstructured":"S\u00e1nchez-Garc\u00eda A, et al. Effect of sodium-glucose co-transporter 2 inhibitors on lipid profile: A systematic review and meta-analysis of 48 randomized controlled trials. Pharmacol Res. 2020;160:105068.","journal-title":"Pharmacol Res"},{"key":"800_CR35","doi-asserted-by":"publisher","first-page":"105781","DOI":"10.1016\/j.phrs.2021.105781","volume":"172","author":"S Wang","year":"2021","unstructured":"Wang S, et al. Protective effect of isosteviol sodium against LPS-induced multiple organ injury by regulating of glycerophospholipid metabolism and reducing macrophage-driven inflammation. Pharmacol Res. 2021;172:105781.","journal-title":"Pharmacol Res"},{"issue":"3","key":"800_CR36","doi-asserted-by":"publisher","first-page":"151281","DOI":"10.1016\/j.semnephrol.2022.10.007","volume":"42","author":"RJ Nicholson","year":"2022","unstructured":"Nicholson RJ, Holland WL, Summers SA. Ceramides and Acute Kidney Injury. Semin Nephrol. 2022;42(3):151281.","journal-title":"Semin Nephrol"},{"issue":"11","key":"800_CR37","first-page":"1051","volume":"1","author":"SA Summers","year":"2019","unstructured":"Summers SA, Chaurasia B, Holland WL. Metabolic Messengers: ceramides Nat Metab. 2019;1(11):1051\u20138.","journal-title":"Metabolic Messengers: ceramides Nat Metab"},{"key":"800_CR38","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1146\/annurev-physiol-031620-093815","volume":"83","author":"B Chaurasia","year":"2021","unstructured":"Chaurasia B, Summers SA. Ceramides in Metabolism: Key Lipotoxic Players. Annu Rev Physiol. 2021;83:303\u201330.","journal-title":"Annu Rev Physiol"},{"key":"800_CR39","doi-asserted-by":"publisher","first-page":"101053","DOI":"10.1016\/j.plipres.2020.101053","volume":"79","author":"K Brejchova","year":"2020","unstructured":"Brejchova K, et al. Understanding FAHFAs: From structure to metabolic regulation. Prog Lipid Res. 2020;79:101053.","journal-title":"Prog Lipid Res"},{"issue":"3","key":"800_CR40","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1194\/jlr.P040501","volume":"55","author":"M Herman-Edelstein","year":"2014","unstructured":"Herman-Edelstein M, et al. Altered renal lipid metabolism and renal lipid accumulation in human diabetic nephropathy. J Lipid Res. 2014;55(3):561\u201372.","journal-title":"J Lipid Res"},{"key":"800_CR41","doi-asserted-by":"crossref","unstructured":"Opazo-R\u00edos L, et al. Lipotoxicity and diabetic nephropathy: novel mechanistic insights and therapeutic opportunities. Int J Mol Sci. 2020;21(7).","DOI":"10.3390\/ijms21072632"},{"issue":"2","key":"800_CR42","doi-asserted-by":"publisher","first-page":"c81","DOI":"10.1159\/000314656","volume":"116","author":"B Rodr\u00edguez-Iturbe","year":"2010","unstructured":"Rodr\u00edguez-Iturbe B, Garc\u00eda Garc\u00eda G. The role of tubulointerstitial inflammation in the progression of chronic renal failure. Nephron Clin Pract. 2010;116(2):c81\u20138.","journal-title":"Nephron Clin Pract"},{"issue":"9","key":"800_CR43","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.nutres.2014.08.005","volume":"34","author":"JS Cho","year":"2014","unstructured":"Cho JS, et al. Serum phospholipid monounsaturated fatty acid composition and \u2206-9-desaturase activity are associated with early alteration of fasting glycemic status. Nutr Res. 2014;34(9):733\u201341.","journal-title":"Nutr Res"},{"issue":"1","key":"800_CR44","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/S1674-8301(10)60003-6","volume":"24","author":"Y Shi","year":"2010","unstructured":"Shi Y. Emerging roles of cardiolipin remodeling in mitochondrial dysfunction associated with diabetes, obesity, and cardiovascular diseases. J Biomed Res. 2010;24(1):6\u201315.","journal-title":"J Biomed Res"},{"issue":"1","key":"800_CR45","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s12964-023-01399-4","volume":"22","author":"Y Hao","year":"2024","unstructured":"Hao Y, et al. ALCAT1-mediated abnormal cardiolipin remodelling promotes mitochondrial injury in podocytes in diabetic kidney disease. Cell Commun Signal. 2024;22(1):26.","journal-title":"Cell Commun Signal"},{"issue":"3","key":"800_CR46","doi-asserted-by":"publisher","first-page":"e70419","DOI":"10.1111\/jcmm.70419","volume":"29","author":"Z Li","year":"2025","unstructured":"Li Z, et al. Renal Lipid Alterations From Diabetes to Early-Stage Diabetic Kidney Disease and Mitophagy: Focus on Cardiolipin. J Cell Mol Med. 2025;29(3):e70419.","journal-title":"J Cell Mol Med"},{"issue":"6451","key":"800_CR47","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1126\/science.aav3722","volume":"365","author":"B Chaurasia","year":"2019","unstructured":"Chaurasia B, et al. Targeting a ceramide double bond improves insulin resistance and hepatic steatosis. Science. 2019;365(6451):386\u201392.","journal-title":"Science"},{"issue":"10","key":"800_CR48","doi-asserted-by":"publisher","first-page":"114746","DOI":"10.1016\/j.celrep.2024.114746","volume":"43","author":"W Xu","year":"2024","unstructured":"Xu W, et al. Ceramide synthesis inhibitors prevent lipid-induced insulin resistance through the DAG-PKC\u03b5-insulin receptor(T1150) phosphorylation pathway. Cell Rep. 2024;43(10):114746.","journal-title":"Cell Rep"},{"key":"800_CR49","doi-asserted-by":"crossref","unstructured":"Hammad SM, Lopes-Virella MF. Circulating sphingolipids in insulin resistance, diabetes and associated complications. Int J Mol Sci. 2023;24(18).","DOI":"10.3390\/ijms241814015"},{"issue":"1","key":"800_CR50","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.plipres.2005.11.002","volume":"45","author":"SA Summers","year":"2006","unstructured":"Summers SA. Ceramides in insulin resistance and lipotoxicity. Prog Lipid Res. 2006;45(1):42\u201372.","journal-title":"Prog Lipid Res"},{"issue":"1","key":"800_CR51","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1038\/s41467-025-56891-x","volume":"16","author":"Z Zhu","year":"2025","unstructured":"Zhu Z, et al. CerS6 links ceramide metabolism to innate immune responses in diabetic kidney disease. Nat Commun. 2025;16(1):1528.","journal-title":"Nat Commun"},{"key":"800_CR52","doi-asserted-by":"publisher","first-page":"100600","DOI":"10.1016\/j.jbc.2021.100600","volume":"296","author":"YG Gao","year":"2021","unstructured":"Gao YG, et al. Ceramide-1-phosphate transfer protein (CPTP) regulation by phosphoinositides. J Biol Chem. 2021;296:100600.","journal-title":"J Biol Chem"},{"issue":"4","key":"800_CR53","doi-asserted-by":"publisher","first-page":"e54731","DOI":"10.15252\/embr.202254731","volume":"24","author":"L Chen","year":"2023","unstructured":"Chen L, et al. Saturated fatty acids increase LPI to reduce FUNDC1 dimerization and stability and mitochondrial function. EMBO Rep. 2023;24(4):e54731.","journal-title":"EMBO Rep"},{"issue":"3","key":"800_CR54","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.ekir.2016.12.003","volume":"2","author":"JJ Liu","year":"2017","unstructured":"Liu JJ, et al. Profiling of Plasma Metabolites Suggests Altered Mitochondrial Fuel Usage and Remodeling of Sphingolipid Metabolism in Individuals With Type 2 Diabetes and Kidney Disease. Kidney Int Rep. 2017;2(3):470\u201380.","journal-title":"Kidney Int Rep"},{"issue":"1","key":"800_CR55","doi-asserted-by":"publisher","first-page":"16398","DOI":"10.1038\/s41598-019-52916-w","volume":"9","author":"N Tofte","year":"2019","unstructured":"Tofte N, et al. Lipidomic analysis reveals sphingomyelin and phosphatidylcholine species associated with renal impairment and all-cause mortality in type 1 diabetes. Sci Rep. 2019;9(1):16398.","journal-title":"Sci Rep"},{"key":"800_CR56","doi-asserted-by":"crossref","unstructured":"Sun ZJ, et al. Deficiency of CFB attenuates renal tubulointerstitial damage by inhibiting ceramide synthesis in diabetic kidney disease. JCI Insight. 2022;7(24).","DOI":"10.1172\/jci.insight.156748"},{"key":"800_CR57","doi-asserted-by":"crossref","unstructured":"Rinaldi A, et al. Impaired fatty acid metabolism perpetuates lipotoxicity along the transition to chronic kidney injury. JCI Insight. 2022;7(18).","DOI":"10.1172\/jci.insight.161783"},{"issue":"8","key":"800_CR58","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nrneph.2016.75","volume":"12","author":"VD D\u2019Agati","year":"2016","unstructured":"D\u2019Agati VD, et al. Obesity-related glomerulopathy: clinical and pathologic characteristics and pathogenesis. Nat Rev Nephrol. 2016;12(8):453\u201371.","journal-title":"Nat Rev Nephrol"},{"issue":"6","key":"800_CR59","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1016\/j.jacl.2018.08.004","volume":"12","author":"BT Steffen","year":"2018","unstructured":"Steffen BT, et al. Circulating oleic acid levels are related to greater risks of cardiovascular events and all-cause mortality: The Multi-Ethnic Study of Atherosclerosis. J Clin Lipidol. 2018;12(6):1404\u201312.","journal-title":"J Clin Lipidol"},{"issue":"6","key":"800_CR60","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1161\/CIRCHEARTFAILURE.112.967802","volume":"5","author":"L Djouss\u00e9","year":"2012","unstructured":"Djouss\u00e9 L, et al. Plasma phospholipid concentration of cis-palmitoleic acid and risk of heart failure. Circ Heart Fail. 2012;5(6):703\u20139.","journal-title":"Circ Heart Fail"},{"issue":"10","key":"800_CR61","doi-asserted-by":"publisher","first-page":"2098","DOI":"10.1007\/s00125-018-4669-0","volume":"61","author":"MC Thomas","year":"2018","unstructured":"Thomas MC, Cherney DZI. The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure. Diabetologia. 2018;61(10):2098\u2013107.","journal-title":"Diabetologia"},{"issue":"10","key":"800_CR62","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1016\/j.cmet.2024.08.005","volume":"36","author":"W Liu","year":"2024","unstructured":"Liu W, et al. SGLT2 inhibitor promotes ketogenesis to improve MASH by suppressing CD8(+) T cell activation. Cell Metab. 2024;36(10):2245\u2013e22616.","journal-title":"Cell Metab"},{"issue":"6","key":"800_CR63","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1016\/j.kint.2021.08.031","volume":"100","author":"SE Piret","year":"2021","unstructured":"Piret SE, et al. Loss of proximal tubular transcription factor Kr\u00fcppel-like factor 15 exacerbates kidney injury through loss of fatty acid oxidation. Kidney Int. 2021;100(6):1250\u201367.","journal-title":"Kidney Int"},{"key":"800_CR64","doi-asserted-by":"publisher","first-page":"1160440","DOI":"10.3389\/fphar.2023.1160440","volume":"14","author":"K Liang","year":"2023","unstructured":"Liang K. Mitochondrial CPT1A: Insights into structure, function, and basis for drug development. Front Pharmacol. 2023;14:1160440.","journal-title":"Front Pharmacol"},{"key":"800_CR65","doi-asserted-by":"crossref","unstructured":"Canini G, et al. Targeting glucosylceramide synthase: innovative drug repurposing strategies for lysosomal diseases. Int J Mol Sci. 2025;26(5).","DOI":"10.3390\/ijms26052195"},{"key":"800_CR66","doi-asserted-by":"publisher","first-page":"104793","DOI":"10.1016\/j.phrs.2020.104793","volume":"156","author":"E Jozefczuk","year":"2020","unstructured":"Jozefczuk E, Guzik TJ, Siedlinski M. Significance of sphingosine-1-phosphate in cardiovascular physiology and pathology. Pharmacol Res. 2020;156:104793.","journal-title":"Pharmacol Res"},{"issue":"1","key":"800_CR67","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1111\/bcpt.12103","volume":"114","author":"S Schwalm","year":"2014","unstructured":"Schwalm S, Pfeilschifter J, Huwiler A. Targeting the sphingosine kinase\/sphingosine 1-phosphate pathway to treat chronic inflammatory kidney diseases. Basic Clin Pharmacol Toxicol. 2014;114(1):44\u20139.","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"7","key":"800_CR68","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1111\/j.1476-5381.2009.00308.x","volume":"157","author":"DY Hui","year":"2009","unstructured":"Hui DY, et al. The phospholipase A(2) inhibitor methyl indoxam suppresses diet-induced obesity and glucose intolerance in mice. Br J Pharmacol. 2009;157(7):1263\u20139.","journal-title":"Br J Pharmacol"},{"key":"800_CR69","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.molmet.2018.07.009","volume":"16","author":"JG Cash","year":"2018","unstructured":"Cash JG, et al. Therapeutic reduction of lysophospholipids in the digestive tract recapitulates the metabolic benefits of bariatric surgery and promotes diabetes remission. Mol Metab. 2018;16:55\u201364.","journal-title":"Mol Metab"},{"issue":"6","key":"800_CR70","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1038\/ijo.2010.215","volume":"35","author":"JG Cash","year":"2011","unstructured":"Cash JG, et al. Pancreatic acinar cell-specific overexpression of group 1B phospholipase A2 exacerbates diet-induced obesity and insulin resistance in mice. Int J Obes (Lond). 2011;35(6):877\u201381.","journal-title":"Int J Obes (Lond)"},{"issue":"1\u20132","key":"800_CR71","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.ejphar.2006.02.043","volume":"536","author":"C Lee","year":"2006","unstructured":"Lee C, et al. Secretory phospholipase A2 induces apoptosis through TNF-alpha and cytochrome c-mediated caspase cascade in murine macrophage RAW 264.7 cells. Eur J Pharmacol. 2006;536(1\u20132):47\u201353.","journal-title":"Eur J Pharmacol"},{"issue":"10","key":"800_CR72","doi-asserted-by":"publisher","first-page":"6433","DOI":"10.4049\/jimmunol.173.10.6433","volume":"173","author":"EJ Jo","year":"2004","unstructured":"Jo EJ, et al. Group IB secretory phospholipase A2 stimulates CXC chemokine ligand 8 production via ERK and NF-kappa B in human neutrophils. J Immunol. 2004;173(10):6433\u20139.","journal-title":"J Immunol"},{"issue":"4","key":"800_CR73","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/s41580-022-00547-x","volume":"24","author":"GR Steinberg","year":"2023","unstructured":"Steinberg GR, Hardie DG. New insights into activation and function of the AMPK. Nat Rev Mol Cell Biol. 2023;24(4):255\u201372.","journal-title":"Nat Rev Mol Cell Biol"}],"container-title":["Biology Direct"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13062-026-00800-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13062-026-00800-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13062-026-00800-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T22:17:17Z","timestamp":1781648237000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13062-026-00800-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,17]]},"references-count":73,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["800"],"URL":"https:\/\/doi.org\/10.1186\/s13062-026-00800-9","relation":{},"ISSN":["1745-6150"],"issn-type":[{"value":"1745-6150","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,17]]},"assertion":[{"value":"3 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The clinical study involving human participants was reviewed and approved by the Medical Ethics Committee of Huai\u2019an First People\u2019s Hospital (Approval No. YX-P-2020-041-01). The trial was registered at the Chinese Clinical Trial Registry on March 10th, 2020 (Registration No. ChiCTR2000033664). Human specimens were collected in accordance with the Declaration of Helsinki and written informed consent was obtained from all participants. The animal experiment was reviewed and approved by the Institutional Animal Care and Use Committee of Nanjing Medical University (Approval No. IACUC-NJMU 2104014). All animal procedures were performed in accordance with relevant guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"50"}}